GlassScriptPhysician profile
Caleb Frett
NPI 1861099574
$2,715.51
in general payments reported to CMS, 2019-2025
30 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $721 · 2023: $197 · 2024: $208 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.32 | 2021-2022 | |
| Abbvie INC. | $403.11 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $300.95 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $300.81 | 2023-2025 | |
| Amgen INC. | $278.18 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.00 | 2021-2025 | Trintellix |
| Myovant Sciences INC. | $108.22 | 2021-2022 | |
| Lilly USA, LLC | $74.14 | 2021 | |
| Pfizer INC. | $73.58 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $63.52 | 2021-2024 | Contrave |
| Supernus Pharmaceuticals, INC. | $51.16 | 2021-2022 | |
| Scynexis, INC. | $47.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.22 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $39.65 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $39.51 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.92 | 2022 | |
| Vivus LLC | $33.88 | 2021-2022 | |
| Melinta Therapeutics, LLC | $28.71 | 2022 | |
| Hologic Sales and Service, LLC | $25.98 | 2022 | |
| Abiomed | $23.96 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $18.96 | 2025 | Voquezna |
| Urovant Sciences INC | $15.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.59 | 2021 | |
| Lupin INC. | $14.88 | 2021 | |
| Exelixis INC. | $14.82 | 2023 | Cabometyx |
| Glaxosmithkline, LLC. | $14.48 | 2021 | |
| Evofem Biosciences, INC. | $14.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.85 | 2022 | |
| Mylan Specialty L.P. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Frett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.